英夫利西单抗联合甲氨蝶呤治疗早期严重类风湿性关节炎

目的了解英夫利西单抗及甲氨蝶呤联合应用对早期严重类风湿性关节炎的临床疗效。方法 78例早期严重类风湿性关节炎患者随机分为英夫利西单抗组、英夫利西单抗联合甲氨蝶呤组及甲氨蝶呤组,治疗前作相应的临床、实验室检查后,英夫利西单抗以每次剂量3 mg/kg静脉滴注,第0、26、周以后每隔8周用药1次;甲氨蝶呤每周10 mg,治疗后对患者临床观察指标进行比较,并进行疗效评价。结果英夫利西单抗联合甲氨蝶呤组治疗24周后,关节炎症症明显得以控制,达到美国风湿学会症状体征20%改善(ACR20)、美国风湿学会症状体征50%改善(ACR50)、美国风湿学会症状体征70%改善(ACR70)的分别为90%、64%及39%,与另外两组比较差异有统计学意义(P<0.01)。结论英夫利西单抗与甲氨蝶呤联合应用对早期严重类风湿性关节炎有显著疗效。

The clinical therapeutic effect of combination of infliximab and MTX on serious rheumatoid arthritis in earlier period

Objective To observe the clinical therapeutic effect of combination of infliximab and MTX on rheumatoid arthritis(RA).Methods 78 cases were randomly divided into 3 groups:the first group were treated with the combination of infliximab and MTX,another infliximab only,the last one MTX only.All the cases were administrated corresponding clinical and laboratory examination.We compared the items about clinic.Meanwhile,The American College of Rheumatology(ACR) core set was used for assessment of efficacy.Results After curling for 24 weeks the inflammation of arthritis of the groups treated with the combination of infliximab and MTX were controlled obviously(P<0.01).24 weeks after completion of treatment,a 20% improvement in ACR was observed in 90%(23/26) of subjects,a 50% improvement in ACR was seen in 64%(16/26) of subjects,and a 70% improvement in ACR was observed in 39%(10/26) of subjects.Conclusion The combination of infliximab and MTX has obvious effect on serious rheumatoid arthritis in earlier period.